Eye | Lasik Specialists | Prince Court Medical Centre | Kuala Lumpur

Prince Court Medical Centre (PCMC)
Address:
39 Jalan Kia Peng
50450 Kuala Lumpur
Malaysia

Contact | Telephone:
Malaysian Hotline: 1-800-88-PCMC
International Hotline: +603 2160 0000

Eye Surgeons | Ophthalmologists | Laser Eye Surgeons:
·         Dr. Tan Niap Hong
·         Prof. Dr. Muhaya Mohamad

Related Terms:
Cataract, contact lens, Eye specialist, laser eye, lasik, ophthalmologist

Comments

Post a Comment

Popular posts from this blog

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
2026 Evidence & Treatment Guide GLP-1 treatment has moved beyond the original Ozempic vs. Wegovy conversation. In 2026, people considering medical treatment for obesity may encounter weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide, and the new oral GLP-1 medicine Foundayo (orforglipron) by Eli Lilly . The important question is no longer simply "Which GLP-1 is strongest?" A better approach is to compare the medicines by indication, clinical evidence, route, tolerability, cardiovascular or sleep-apnea considerations, cost, access, long-term maintenance, and the person's broader health goals. Updated: September 27, 2026   |   Regulatory reference: U.S. FDA labeling   |   Scope: Adult obesity treatment unless otherwise stated Important medical note: This page is educational information, not a diagnosis or personal treatm...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive resistance training, sufficient nutrition a...
Read more

Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss: What the Evidence Shows

Image
Updated September 25, 2026 Popular GLP-1-based medicines are now at the center of a growing legal and medical debate over a rare form of sudden vision loss called nonarteritic anterior ischemic optic neuropathy (NAION) . Patients in the United States have filed lawsuits against the manufacturers of widely used medicines including Ozempic, Wegovy, Mounjaro and Zepbound , alleging that the drugs caused NAION and that patients were not adequately warned about the potential risk. Those lawsuits are allegations at the moment—not findings that the medications caused the injuries. The scientific evidence is still evolving and is not completely consistent. Importantly, the regulatory evidence is stronger for semaglutide , the active ingredient in Ozempic, Wegovy and Rybelsus, than for the entire GLP-1 drug class. Patient safety message: Sudden or rapidly worsening vision loss is not a symptom to monitor at home. Anyone experiencing sudden vision loss while taking a GLP-1-based medi...
Read more

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: August 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection indic...
Read more

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity

Image
By Dr. Frank Yap, MD  |  Originally published April 2026  |  Fully updated August 26, 2026 for the FDA's July 2026 compounding committee vote Quick Answer As of August 2026, GLP-1 receptor agonists (semaglutide, tirzepatide) remain the only peptides in this guide with full FDA approval. On July 23–24, 2026, an FDA advisory committee (PCAC) recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list of substances compounding pharmacies may use — but that vote is non-binding, and none of the six is lawful to compound yet; formal rulemaking is expected to take 12–24 months. Separately, AOD-9604 failed its pivotal human obesity trial back in 2007. The best human evidence among the non-GLP-1 peptides here belongs to topical GHK-Cu (skin) and Selank (anxiety); the weakest belongs to BPC-157 and TB-500 (mostly animal data). Any protocol should run through a licensed physician — not a gray-market vendor. Medical & regu...
Read more

9 Best Berberine Supplements (2026 Review): Evidence, Dosage & New EU Safety Data

Image
By Dr Frank Yap, MD | Medically reviewed by the One Day MD Editorial Team | Last updated: August 2026 | Original publication: March 2023 Quick Answer A 2024–2025 meta-analysis of 50 RCTs (4,150 patients) confirms berberine modestly but reliably lowers fasting glucose, HbA1c, LDL cholesterol and inflammatory markers in type 2 diabetes and metabolic syndrome — solid, Tier 1a evidence. It is not "nature's Ozempic." Semaglutide produces roughly 10–15%+ body-weight loss in trials; berberine averages only about 2–4 lb a month. The mechanisms and effect sizes aren't comparable. Typical dosing is 500 mg, 2–3x daily with meals (1,000–1,500 mg/day). Bioavailability — not the milligram number on the label — is the biggest real difference between brands. New in 2026: A draft EU/UK scientific opinion (EFSA/COT, March 2026) flagged in-vitro genotoxicity signals, confirmed the CYP3A4 drug-interaction risk, and stated that regulators cannot yet establish a formal "...
Read more

NAC vs NAD vs NR vs NMN vs Niacin: What Are the Differences?

Image
By the One Day MD Editorial Team  |  Originally published September 2020  |  Last updated and medically fact-checked: August 2026 NAD, NAD+, NADH, NR, NMN, niacin, niacinamide, and NAC — these overlapping names cause constant confusion, and understandably so. Some are simply different names for the same molecule. Others are metabolic precursors that your body converts, step by step, into NAD+. One of them, NAC, isn't related to NAD+ metabolism at all. This guide breaks down what each compound actually does, how the human evidence stacks up as of 2026, and where the real safety trade-offs lie — including the January 2026 head-to-head human trial that finally pitted NR against NMN directly, and the FDA's 2025 reversal on NMN's legal status. Quick Answer NAD+ is the coenzyme your cells actually need for energy production and DNA repair, and it can't be taken as an oral supplement because it's too large a molecule to survive digestion intact. NR, NMN, n...
Read more

Bryan Johnson's Supplements List: Insider's Guide (2026 Update)

Image
By Editorial Team , medically reviewed by Dr Frank Yap, MD | Last updated: August 2026 | Originally published: June 2024 Related: Bryan Johnson's Blueprint Longevity Mix Review Quick Answer Bryan Johnson's protocol has been substantially simplified since the 40+ item pill list he published in 2024. His January 2026 update replaces most of the granular, individually-dosed compounds (NAC, red yeast rice, DHEA, genistein, standalone taurine, and others) with combined formulations — Essential Capsules, Advanced Antioxidants, and a merged Ashwagandha & Rhodiola product — alongside NR or NMN, omega-3, and Proferrin. His daily creatine dose has increased to 7.5 g total. The bigger change is on the prescription side: he has added three cardiometabolic drugs not previously disclosed — the SGLT2 inhibitor Jardiance (empagliflozin) , the PCSK9 inhibitor Repatha (evolocumab) , and the ARB candesartan — and switched metformin from continuous daily dosing to a s...
Read more

Best Injectable Peptides for Anti Aging 2026

Image
By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Last updated: August 2026 Quick Answer Most content ranking for "injectable peptides for anti-aging" actually describes topical cosmetic peptides (Matrixyl, Argireline, copper peptide serums) that are never injected at all. True injectable anti-aging peptides fall into distinct categories: skin-quality "boosters" used in medical aesthetics (injectable GHK-Cu, growth-factor mesotherapy), growth-hormone secretagogues (sermorelin, tesamorelin, CJC-1295, ipamorelin), regenerative peptides (BPC-157, TB-500), and cellular/metabolic peptides (MOTS-c, epitalon). Evidence quality varies enormously — from large randomized trials (tesamorelin, GLP-1 drugs) down to animal-only data (BPC-157, most "longevity" peptides). As of August 2026, several popular peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon) were recommended by an FDA advisory panel for legal compounding but are not yet...
Read more

Ivermectin for Parkinson’s and Dementia: Analyzing the Neuroprotective Molecular Evidence and Clinical Case Reports (2026)

Image
Scientific Review & Regulatory Audit by the Clinical Editorial Team The therapeutic paradigm for progressive neurodegenerative disorders like Parkinson’s disease (PD) and various forms of dementia faces a critical bottleneck. Standard pharmacology, primarily anchored by levodopa (L-DOPA) for Parkinson’s and acetylcholinesterase inhibitors for dementia, remains strictly symptomatic. These options frequently suffer from diminishing efficacy and significant side-effect profiles like L-DOPA-induced dyskinesia over long-term use. Consequently, the pharmaceutical community has focused heavily on drug repurposing—identifying established, safety-vetted compounds capable of crossing pathways to modify disease progression. An unexpected frontline candidate emerging in this space is ivermectin. Traditionally classified as a broad-spectrum antiparasitic agent, a surge of preclinical studies between 2020 and 2024 has unveiled its complex, multi-targeted pharmacodynamics within the mam...
Read more